Applications of Tenofovir in Industrial Manufacturing

As a leading manufacturer, we supply Tenofovir for multiple downstream sectors, supporting pharmaceutical production and advanced formulation of critical healthcare products. Our material meets stringent international and local standards, providing high purity suitable for regulated industrial applications. Below we outline core application fields, with details on compliance, process integration, ratio guidelines, and resulting products.

1. Antiviral Solid Oral Dose Pharmaceuticals

Tenofovir is a key active pharmaceutical ingredient for the manufacture of oral antivirals, especially in the treatment of chronic hepatitis B and HIV-1 infection. Downstream formulators utilize our material for high-volume tablet and capsule production, requiring consistent assay, low impurity profiles, and proven stability during the granulation and compression process. The ingredient enters at the blending stage, proceeding through wet or dry granulation, and precise compression calibration, followed by film-coating and controlled packaging lines, maintaining validated traceability.

Industry compliance standards

• USP, Ph. Eur. (Monographs for Tenofovir Disoproxil Fumarate)
• WHO Prequalification of Medicines Programme
• ICH Q7 GMP for APIs
• SFDA, EMA, US FDA filing requirements

Typical usage ratio

• Typically 245 mg Tenofovir disoproxil fumarate per tablet (equivalent to 300 mg Tenofovir disoproxil)
• Ratio adjusted for pediatric formulations, fixed-dose combinations, and dissolution profile targeting

Downstream process integration

• Direct addition at blending/granulation step in high-shear or fluid bed equipment
• Inline blending with excipients such as lactose, microcrystalline cellulose, croscarmellose, and magnesium stearate
• Quality control in-process checks on content uniformity before compaction

Final product types

• Chronic hepatitis B oral tablets
• HIV-1 fixed dose combination tablets (with emtricitabine, lamivudine, or efavirenz)
• Pediatric dispersible tablets
• Extended-release oral formulations

2. Antiretroviral Oral Suspension Formulations

Liquid oral suspension manufacturing uses Tenofovir for specialized populations, such as pediatrics or patients with swallowing difficulties. Our pharmaceutical raw material supports safe dosing accuracy through controlled micronization or special particle engineering, providing homogenous dispersion in aqueous vehicles. The ingredient introduction utilizes high-shear mixing followed by homogenization, pH adjustment, and in-process endotoxin control, ensuring stability and reproducibility in filling and sealing operations within GMP-compliant environments.

Industry compliance standards

• WHO Model Formulary for Children
• US cGMP (21 CFR Part 210/211)
• ICH Q3C/Q3D for residual solvents and elemental impurities
• ICH Q1A for stability requirements

Typical usage ratio

• Final suspension concentration: 10 mg Tenofovir per mL aqueous solution
• Dose and ratio adjusted for patient weight group, up to 600 mg daily administered in divided doses

Downstream process integration

• Dispersion into buffered vehicles (e.g., sodium citrate/citric acid buffer) in jacketed reactors
• Homogenization under sterile conditions prior to aseptic filtration and bottling
• Routine particle size analysis and viscosity monitoring for batch release

Final product types

• Pediatric oral suspensions for HIV or HBV
• Ready-to-use hospital liquid units
• Compounded extemporaneous formulations
• Preservative-free multidose bottles

3. Active Ingredient for Pre-Exposure Prophylaxis Drug Products (PrEP)

Tenofovir supplies for PrEP drug manufacturing must comply with global regulatory expectations for high safety and reliability profiles. Manufacturers deploy the ingredient during fixed-dose combination tableting, commonly paired with emtricitabine, using high-volume, automated lines. Stringent identity, purity, and dissolution testing apply from raw material receipt to final batch release, supporting robust supply chains for international public health programs. Our controlled particle size distribution and validated handling protocol support consistent product safety and performance in preventive therapy rollouts.

Industry compliance standards

• US FDA Abbreviated New Drug Application (ANDA) guidelines for PrEP
• Global Fund QA policies for API suppliers
• PIC/S GMP convention
• WHO Essential Medicines List specifications

Typical usage ratio

• 200 mg to 300 mg Tenofovir disoproxil per daily oral dose
• Combination ratio with emtricitabine fixed (1:1.5 standard w/w), adjusted for local labeling

Downstream process integration

• Metered dry blending with co-formulated APIs in automated weighing systems
• Direct compression tableting or fluid bed granulation, followed by in-line film coating
• Batch traceability retained throughout process chain

Final product types

• PrEP fixed-dose combination tablets (e.g., TDF/FTC tablets)
• Non-branded (generic) PrEP products supplied to global tender markets
• Alternative labeled regional PrEP products
• Restricted access prophylaxis packs for clinical deployment

4. Starting Material for Antiviral API Contract Manufacturing

CDMO and API contract manufacturers incorporate Tenofovir as a core building block for synthesizing tenofovir derivatives and analogues. Our high-purity product supports further chemical conversion to prodrugs (such as Tenofovir disoproxil fumarate, Tenofovir alafenamide) via established multi-stage chemical syntheses. Supply requires full analytical documentation, impurity profiling, and packaging validation under GDP. Material enters at defined reaction steps, supporting modular and continuous flow synthesis lines under validated batch records, with precise mass balance tracking and solvent recovery systems.

Industry compliance standards

• ICH Q11: Development and Manufacture of Drug Substances
• US DMF Type II registration
• ISO 9001:2015 for API production management
• Regional Ministry of Health raw material import licenses

Typical usage ratio

• Input as principal precursor: 1 mol Tenofovir per batch, stoichiometry adjusted per output yield and target derivative
• Guidelines based on final conversion efficiency (60%-80% yield typical for phosphate prodrug synthesis)

Downstream process integration

• Addition at controlled temperature reaction (alkylation, esterification steps)
• In-process controls for reaction completion, impurity monitoring via HPLC/UPLC
• Downstream purification by recrystallization, washing, and drying under vacuum

Final product types

• Tenofovir disoproxil fumarate (TDF) API bulk
• Tenofovir alafenamide (TAF) intermediate
• Chemically modified phosphate analogues (research use)
• Export-grade tenofovir for secondary syntheses